| abstract |
Anticancer fusion protein The present invention describes a fusion protein comprising domain (a) which is a functional fragment of htrail protein sequence, which fragment starts with an amino acid at a position not less than htrail 95, or a homolog of said fragment functional which has at least 70% sequence identity, preferably 85% identity and ending with the amino acid htrail281; and at least one domain (b) which is a pore-forming cytolytic effector peptide sequence in the cell membrane, wherein the domain sequence (b) is attached to the c-terminus or n-terminus of domain (a). the fusion protein can be used to treat cancer diseases. |